Evidence map›Paper›PMID 27507111›Full record

Observational studyCirculation. Heart failure2016

Frequency of Poor Outcome (Death or Poor Quality of Life) After Left Ventricular Assist Device for Destination Therapy: Results From the INTERMACS Registry.

Suzanne V Arnold, Philip G Jones, Larry A Allen, David J Cohen, Timothy J Fendler, Jonathan E Holtz, Sanjeev Aggarwal, John A Spertus

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation.American heart journal plus : cardiology research and practice · 2022
    Article
  8. Review
  9. Is Left Ventricular Assist Device Deactivation Ethically Acceptable? A Study on the Euthanasia Debate.HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Suzanne V ArnoldFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.). suz.v.arnold@gmail.com.
Philip G JonesFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).
Larry A AllenFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).
David J CohenFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).
Timothy J FendlerFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).
Jonathan E HoltzFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).
Sanjeev AggarwalFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).
John A SpertusFrom the Saint Luke's Mid America Heart Institute, Kansas City, MO (S.V.A., P.G.J., D.J.C., T.J.F., S.A., J.A.S.); University of Missouri-Kansas City (S.V.A., D.J.C., T.J.F., J.A.S.); University of Colorado, Denver (L.A.A.); and University of Pittsburgh, PA (J.E.H.).

Funding

CARDIOVASCULAR OUTCOMES RESEARCH TRAINING PROGRAMT32HL110837 · NHLBI · UNIVERSITY OF MISSOURI KANSAS CITY · PI JOHN A SPERTUS · 2012 to 2026
$5.0M
Optimal Decision Making in Aortic Valve ReplacementK23HL116799 · NHLBI · SAINT LUKE'S HOSPITAL · PI ARNOLD, SUZANNE VICTORIA · 2014 to 2018
$635k
NHLBI NIH HHS HHSN268201100025CNHLBI NIH HHS K23 HL116799NHLBI NIH HHS T32 HL110837
6 · The paper itself

Abstract

backgroundA left ventricular assist device (LVAD) improves survival and quality of life for many, but not all, patients with end-stage heart failure who are ineligible for transplantation. We sought to evaluate the frequency of poor outcomes using a novel composite measure that integrates quality of life with mortality. METHODS AND

resultsWithin the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) national registry, poor outcome was defined as death or an average Kansas City Cardiomyopathy Questionnaire <45 during the year after LVAD (persistently limiting heart failure symptoms and poor quality of life). Among 1638 patients with LVAD, 29.7% had a poor outcome, with death in 22.4% and persistently poor quality of life in 7.3%. Patients who had a poor outcome were more likely to have higher body mass indices (29.3 versus 28.2 kg/m(2); P=0.007), lower hemoglobin levels (11.1 versus 11.4 g/dL; P=0.005), previous cardiac surgery (47.8% versus 39.8%; P=0.004), history of cancer (13.8% versus 9.7%; P=0.025), severe diabetes mellitus (15.6% versus 11.5%; P=0.038), and poorer quality of life preimplant (Kansas City Cardiomyopathy Questionnaire scores: 29.8 versus 35.3; P<0.001).

conclusionsNearly one third of patients die or have a persistently poor quality of life during the year after LVAD. We identified several factors associated with a poor outcome, which may inform discussions before LVAD implantation to enable more realistic expectations of recovery.

Indexed as

Heart-Assist DevicesVentricular Function, LeftAdultAgedDecision Support TechniquesFemaleHeart FailureHumansMaleMiddle AgedPatient SelectionQuality of LifeRecovery of FunctionRegistriesRisk AssessmentRisk Factorsheart failurequality of lifeventricular assist device

Identifiers

PMID27507111
PMCPMC4985017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.